Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a neck injection quiet the Brain's fear response in PTSD?

NCT ID NCT05391971

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether injecting an anesthetic near certain neck nerves (stellate ganglion block) can reduce PTSD symptoms by calming overactive stress responses. About 79 adults with chronic PTSD will receive either the anesthetic or a placebo (saline) injection. Researchers will measure changes in brain activity and skin sweat responses before and after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine (anesthetic)
What this could lead to
If it works, this could offer a new, non-drug option to ease PTSD symptoms by temporarily calming the body's stress alarm system.
What could go wrong
This is a small, early-stage trial with only 79 participants, so results may not apply to everyone. The effect may be short-lived or no better than a placebo injection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

79 people

The number who actually took part.

Started

Aug 2022

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18-65 years of age 2. Chronic (at least one month post-trauma) DSM-5 PTSD symptoms 3. CAPS-5 Past Month score ≥ 26 4. Meets current DSM-5 PTSD diagnosis 5. Stable medications for 3 or more months by the time of study entrance (with the exception of benzodiazepines) 6. Willing and able to provide informed consent Exclusion Criteria: 1. History of stellate ganglion block treatment 2. Allergy to local anesthetics (e.g. ropivacaine, bupivacaine) 3. Allergy to iodinated contrast agents 4. Diagnosis of bipolar I disorder with a past year manic episode 5. Diagnosis of a psychotic disorder or psychotic symptoms 6. Diagnosis of current moderate or severe substance use disorder 7. History of neurological disease (that involves the brain), seizure, or significant head trauma (i.e., extended loss of consciousness, neurological sequelae, or known structural brain lesion) 8. Significant recent suicidal ideation or significant suicidal behavior in the past 12 months or suicidal ideation with imminent risk that warrants a higher level of care 9. Concurrent trauma focused psychotherapy 10. Pregnancy (to be ruled out by urine ß-HCG) 11. Metallic implants or devices contraindicating magnetic resonance imaging by interfering with patient safety or fMRI data collection; cases will be cleared by the Principal Investigator and Center for Brain Imaging 12. Morbid obesity (BMI \>4 kg/m2) 13. Current use of opioids, cocaine, or benzodiazepines (as assessed by urine toxicology) 14. Self-injurious behavior that involves suicidal intent, requires medical attention, or occurs daily. 15. Cardiac conditions or any prior heart surgeries 16. Respiratory conditions such as COPD or untreated asthma 17. History of heavy metal poisoning 18. History of neck or throat surgeries 19. Vocal cord problems or paralysis 20. Untreated high blood pressure 21. Current cancer diagnosis 22. Diagnosis of Guillain-Barré syndrome 23. Diagnosis of Parkinson's Disease 24. Unable to take 7 days off of blood thinners

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post traumatic stress disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.